NatiMab Therapeutics S.r.l.
Via Ribes
10010 Colleretto Giacosa (TO), Italy

Project leader

Prof. Gianni Garotta

Phone: +41 794 581266
Fax: +39 125 538791

Institute presentation

NatiMab Therapeutics S.r.l. is a biotechnology company dedicated to the discovery, development and commercialization of human monoclonal antibodies for the therapeutic management of infectious diseases and cancer.

Our fully human antibodies have an advantage over other fully human antibodies because we identify the antibodies out of the B cell repertoire of patients who have acquired immunity to the target of interest. Thus, the antibodies have been selected and matured in the human body and are more likely to have a potent effect in fighting the infection or tumor.

NatiMab was founded in 2008 as a private company registered with the Torino commercial registry (09730260016). The corporate headquarters for NatiMab Therapeutics S.r.l. is located in Colleretto Giacosa (Torino) Italy.

NatiMab has focused its activities on the ENOA (α-Enolase) as a marker for pancreas adenocarcinoma, on the generation of diagnostic test, therapeutic antibodies and/or therapeutic vaccination for pancreas adenocarcinoma.

The assets developed by NatiMab may be licensed out to larger biotech or pharmaceutical companies or co-developed through strategic alliances with such companies.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Until you give your consent, only those cookies necessary to maintain the website's functionality are active. When you choose "OK", so called third-party non-functional cookies (e.g. GDPR-conform Google Analytics) may also become active. Please be aware that the website's functionality may be restricted if you choose "DECLINE". You can revoke your choice at any time by clearing your browser cache/history and updating your selection. Please also view our privacy policy.